News >

Ruxolitinib Combo Shows Potential in Post-MPN AML, But Unmet Need Remains

Caroline Seymour
Published: Wednesday, Mar 18, 2020

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Prithviraj Bose, MD

The combination of ruxolitinib (Jakafi) and decitabine is a viable alternative to intensive chemotherapy with comparable response rates in patients with post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML), according to findings from a phase I/II study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication